Revenue Misses Trigger Sharp Sell-Offs for Zevia and Chemed in Q4 Earnings
Zevia and Chemed both reported fourth-quarter revenue that fell short of analyst expectations, leading to significant stock price declines. While Zevia managed a slight EPS beat, Chemed saw a dramatic 14.7% plunge as investors prioritized top-line growth and guidance over narrow margin improvements.